Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

Insmed (INSM) has announced the granting of inducement awards to 66 new employees as approved by its Compensation Committee, in compliance with NASDAQ Listing Rule 5635(c)(4). On February 3, 2025, the employees received options to purchase a total of 108,860 shares of Insmed common stock at an exercise price of $77.88 per share, which was the closing price on the Nasdaq Global Select Market on the grant date.

The stock options come with a 10-year term and a four-year vesting schedule. The vesting terms include 25% of shares vesting on the first anniversary of the grant date, followed by 12.5% vesting every six months through the fourth anniversary, contingent upon continued employment with Insmed.

Positive

• Expansion of workforce with 66 new employees indicating company growth
• Alignment of employee interests with shareholders through equity compensation

Negative

• Potential dilution of existing shareholders due to 108,860 new stock options

News Market Reaction

-1.03%

1 alert

-1.03% News Effect

On the day this news was published, INSM declined 1.03%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

BRIDGEWATER, N.J., Feb. 7, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 66 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.

In connection with the commencement of their employment, the employees received options on February 3, 2025 to purchase an aggregate 108,860 shares of Insmed common stock at an exercise price of $77.88 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.

The options have a 10-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the relevant grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary of the relevant grant date, subject to the relevant employee's continued service with Insmed on the applicable vesting date.

About Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending four consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more.

Contact:

Investors:

Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
bryan.dunn@insmed.com

Michael V. Morabito, Ph.D.
Director, Investor Relations
(917) 936-8430
michael.morabito@insmed.com 

Gianna De Palma
Manager, Investor Relations
(973) 886-2236
gianna.depalma@insmed.com 

Media:

Mandy Fahey
Vice President, Corporate Communications
(732) 718-3621
amanda.fahey@insmed.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302370675.html

SOURCE Insmed Incorporated

FAQ

How many shares were granted in Insmed's (INSM) February 2025 inducement awards?

Insmed granted options to purchase 108,860 shares of common stock to 66 new employees.

What is the exercise price for Insmed's (INSM) February 2025 inducement stock options?

The exercise price for the stock options is $77.88 per share, which was the closing price on the Nasdaq Global Select Market on February 3, 2025.

What is the vesting schedule for Insmed's (INSM) February 2025 inducement options?

The options have a four-year vesting schedule with 25% vesting after one year and 12.5% vesting every six months thereafter through the fourth anniversary.

How long is the term of Insmed's (INSM) February 2025 inducement stock options?

The stock options have a 10-year term.